廣告
香港股市 將收市,收市時間:2 小時 17 分鐘
  • 恒指

    16,558.60
    -178.50 (-1.07%)
     
  • 國指

    5,794.23
    -53.92 (-0.92%)
     
  • 上證綜指

    3,075.16
    -9.77 (-0.32%)
     
  • 滬深300

    3,593.56
    -9.97 (-0.28%)
     
  • 美元

    7.8203
    +0.0015 (+0.02%)
     
  • 人民幣

    0.9200
    -0.0001 (-0.01%)
     
  • 道指

    38,790.43
    +75.63 (+0.20%)
     
  • 標普 500

    5,149.42
    +32.33 (+0.63%)
     
  • 納指

    16,103.45
    +130.25 (+0.82%)
     
  • 日圓

    0.0518
    -0.0004 (-0.79%)
     
  • 歐元

    8.4954
    -0.0058 (-0.07%)
     
  • 英鎊

    9.9370
    -0.0130 (-0.13%)
     
  • 紐約期油

    82.50
    -0.22 (-0.27%)
     
  • 金價

    2,161.60
    -2.70 (-0.12%)
     
  • Bitcoin

    64,988.10
    -3,729.86 (-5.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets.

  • Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens.

  • For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin.

  • Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners.

  • Zymergen will oversee all validation.

  • Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.